Evidence map›Paper›PMID 26666768›Full record

ArticleDer Nervenarzt2016

[Psychotherapy and pharmacotherapy for harmful tobacco use and tobacco dependency].

A Batra, K U Petersen, E Hoch, K Mann, C Kröger, C Schweizer, A Jähne, T Rüther, N Thürauf, S Mühlig

Abstract read
PubMed Publisher
In one paragraph

Article in Der Nervenarzt, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 2 countries.

A BatraSektion Suchtforschung und Suchttherapie, Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Tübingen, Calwer Str. 14, 72076, Tübingen, Deutschland. anil.batra@med.uni-tuebingen.de.
K U PetersenSektion Suchtforschung und Suchttherapie, Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Tübingen, Calwer Str. 14, 72076, Tübingen, Deutschland.
E HochKlinik für Abhängiges Verhalten und Suchtmedizin, Zentralinstitut für Seelische Gesundheit, Mannheim, Deutschland.
K MannKlinik für Abhängiges Verhalten und Suchtmedizin, Zentralinstitut für Seelische Gesundheit, Mannheim, Deutschland.
C KrögerInstitut für Therapieforschung (IfT), München, Deutschland.
C SchweizerMilton-Erickson-Gesellschaft, Tübingen, Deutschland.
A JähneRhein-Jura-Klinik, Bad Säckingen, Deutschland.
T RütherKlinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, München, Deutschland.
N ThüraufPsychiatrische und Psychotherapeutische Klinik, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Deutschland.
S MühligInstitut für Psychologie, Klinische Psychologie und Psychotherapie, Technische Universität Chemnitz, Chemnitz, Deutschland.
Universitätsklinikum Tübingen · DEAcura Kliniken · DECentral Institute of Mental Health · DEChemnitz University of Technology · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEIFT Institut für Therapieforschung · DEKlinik und Poliklinik für Psychiatrie und Psychotherapie · DEThe Milton H. Erickson Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tobacco consumption is one of the major preventable health risk factors. In Germany approximately 110,000 people prematurely die from tobacco-related diseases and approximately 50% of regular smokers are considered to be tobacco dependent. Nevertheless, motivation to quit smoking is low and the long-term abstinence rates after attempts to stop smoking without professional support are far below 10%. As part of the S3 treatment guidelines 78 recommendations for motivation and early interventions for smokers unwilling to quit as well as psychotherapeutic and pharmacological support for smokers willing to quit were formulated after an systematic search of the current literature. More than 50 professional associations adopted the recommendations and background information in a complex certification process. In this article the scientific evidence base regarding the psychotherapeutic and pharmacological treatment options as well as recommendations and further information about indications and treatment implementation are presented. By following these guidelines for treatment of heavy smokers who are willing to quit combined with individual and group therapies on the basis of behavioral treatment strategies and pharmacological support, long-term success rates of almost 30% can be achieved.

Indexed as

Practice Guidelines as TopicEvidence-Based MedicineGermanyGuideline AdherenceHumansNeurologyPsychiatryPsychotherapyTobacco Use CessationTobacco Use Cessation DevicesTobacco Use DisorderTreatment OutcomePharmacotherapyPsychotherapySubstance-related disordersTobacco use disordersTreatment practice guidelines

Identifiers

PMID26666768
OpenAlexW2206399423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.